BIO-TECHNE Corp vs Vale SA — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Vale SA trades at $13.6 (market cap $57.32B). The key difference: Vale SA is far larger — about 5× BIO-TECHNE Corp's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vale SA for 109 Days on average.
| TECH | VALE | |
|---|---|---|
Market Cap | $11.36B | $57.32B |
Volume | 5,390,331 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $72.61 | $17.82 |
52-Week Low | $43.31 | $10.75 |
Typical Hold Time | 63 Days | 109 Days |
Enterprise Value | $11.39B | $73.56B |
Dividend Yield | 0.44% | 8.87% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VALE trades at $13.61, down 3.34% amid broader market weakness in mining stocks. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but iron ore pricing pressure and rising costs challenge near-term profitability. Analyst consensus remains mixed with 32% buy ratings despite a $16.21 price target suggesting 19% upside potential.
The investment case balances Vale's position as a low-cost iron ore producer against cyclical commodity exposure and Brazilian regulatory risks. Base metals growth provides diversification, but margin compression and debt increases warrant caution. Current valuation at 27x P/E appears stretched given earnings volatility, making risk-reward balanced for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →